A census of predicted mutational epitopes suitable for immunologic cancer control

Human Immunology

Volumn 71, Issue 3, 2010, Pages 245-254

  Warren, René L ^a   Holt, Robert A ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Cancer immunity; Cancer vaccine; Epitope prediction; Immunosurveillance; T cell epitope

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; MUTANT PROTEIN; PEPTIDE DERIVATIVE;

ADAPTIVE IMMUNITY; ALLELE; ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER PREVENTION; MALIGNANT NEOPLASTIC DISEASE; MUTATIONAL ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RECURRENT CANCER; SOMATIC MUTATION;

ADAPTIVE IMMUNITY; ALGORITHMS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; COMPUTATIONAL BIOLOGY; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; MUTATION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 76949105768     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.12.007     Document Type: Article

References (43)

1. Ehrlich P. Experimentelle Karzinom-studien on Mausen. Arch Inst Exp Ther 1 (1906) 65
2. Bashford E., Murray J., Haaland M., and Bowen W. General results of propagation of malignant new growths. In: Bashford E. (Ed). Third Scientific Report on the Investigations of the Imperial Cancer Research Fund (1908), Taylor and Francis, London
3. Prehn R.T., and Main J.M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18 (1957) 769-778
4. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
5. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
6. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
7. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
8. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
9. Cefai D., Morrison B.W., Sckell A., Favre L., Balli M., Leunig M., et al. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 83 (1999) 393-400
10. Dakappagari N.K., Douglas D.B., Triozzi P.L., Stevens V.C., and Kaumaya P.T. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 60 (2000) 3782-3789
11. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194 (2001) 1195-1205
12. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 174 (2005) 4228-4236
13. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
14. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 61 (1996) 274-278
15. Suranyi M.G., Hogan P.G., Falk M.C., Axelsen R.A., Rigby R., Hawley C., et al. Advanced donor-origin melanoma in a renal transplant recipient: Immunotherapy, cure, and retransplantation. Transplantation 66 (1998) 655-661
16. MacKie R.M., Reid R., and Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 348 (2003) 567-568
17. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohme I., Forsberg B., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 60 (1995) 183-189
18. Mihm M.C., Clemente C.G., and Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74 (1996) 43-47
19. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
20. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
21. Reuschenbach M., von Knebel Doeberitz M., and Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58 (2009) 1535-1544
22. Wang H.Y., Zhou J., Zhu K., Riker A.I., Marincola F.M., and Wang R.F. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: Its role in extracellular matrix formation and tumor metastasis. J Exp Med 195 (2002) 1397-1406
23. Gaudin C., Kremer F., Angevin E., Scott V., and Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 162 (1999) 1730-1738
24. Huang J., El-Gamil M., Dudley M.E., Li Y.F., Rosenberg S.A., and Robbins P.F. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 172 (2004) 6057-6064
25. Linard B., Bezieau S., Benlalam H., Labarriere N., Guilloux Y., Diez E., et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 168 (2002) 4802-4808
26. Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183 (1996) 1185-1192
27. Kawakami Y., Wang X., Shofuda T., Sumimoto H., Tupesis J., Fitzgerald E., et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol 166 (2001) 2871-2877
28. Lollini P.L., Cavallo F., Nanni P., and Forni G. Vaccines for tumour prevention. Nat Rev Cancer 6 (2006) 204-216
29. Gjertsen M.K., Bjorheim J., Saeterdal I., Myklebust J., and Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72 (1997) 784-790
30. Ito D., Visus C., Hoffmann T.K., Balz V., Bier H., Appella E., et al. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer 120 (2007) 2618-2624
31. Messaoudi I., Guevara Patino J.A., Dyall R., LeMaoult J., and Nikolich-Zugich J. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 298 (2002) 1797-1800
32. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91 (2004) 355-358
33. Forbes S., Clements J., Dawson E., Bamford S., Webb T., Dogan A., et al. COSMIC 2005. Br J Cancer 94 (2006) 318-322
34. Forbes S.A., Bhamra G., Bamford S., Dawson E., Kok C., Clements J., et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) Chapter 10:Unit 10.11
35. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., and Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
36. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152 (1994) 163-175
37. Peters B., Sidney J., Bourne P., Bui H.H., Buus S., Doh G., et al. The design and implementation of the immune epitope database and analysis resource. Immunogenetics 57 (2005) 326-336
38. Peters B., and Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6 (2005) 132
39. Kessler J.H., and Melief C.J. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21 (2007) 1859-1874
40. Gulukota K., and DeLisi C. HLA allele selection for designing peptide vaccines. Genet Anal 13 (1996) 81-86
41. Kessler J.H., Mommaas B., Mutis T., Huijbers I., Vissers D., and Benckhuijsen W.E. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 64 (2003) 245-255
42. Pushkarev D., Neff N.F., and Quake S.R. Single-molecule sequencing of an individual human genome. Nat Biotechnol 27 (2009) 847-852
43. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532